JP Morgan Chase’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.07M | Sell |
754,782
-19,630
| -3% | -$91.3K | ﹤0.01% | 3758 |
|
|
2025
Q4 | $4.26M | Buy |
774,412
+478,168
| +161% | +$2.32M | ﹤0.01% | 3468 |
|
|
2025
Q3 | $969K | Buy |
296,244
+73,595
| +33% | +$208K | ﹤0.01% | 4622 |
|
|
2025
Q2 | $514K | Sell |
222,649
-780,418
| -78% | -$1.7M | ﹤0.01% | 4767 |
|
|
2025
Q1 | $1.39M | Sell |
1,003,067
-1,640,688
| -62% | -$2.74M | ﹤0.01% | 4124 |
|
|
2024
Q4 | $4.57M | Sell |
2,643,755
-357,642
| -12% | -$742K | ﹤0.01% | 3436 |
|
|
2024
Q3 | $6.03M | Buy |
3,001,397
+37,844
| +1% | +$83K | ﹤0.01% | 3082 |
|
|
2024
Q2 | $6.64M | Buy |
2,963,553
+2,869,812
| +3,061% | +$8.35M | ﹤0.01% | 2814 |
|
|
2024
Q1 | $269K | Buy |
93,741
+57,257
| +157% | +$119K | ﹤0.01% | 5180 |
|
|
2023
Q4 | $64.6K | Buy |
36,484
+36,347
| +26,531% | +$72.5K | ﹤0.01% | 5916 |
|
|
2023
Q3 | $433 | Sell |
137
-1,645
| -92% | -$3.07K | ﹤0.01% | 6746 |
|
|
2023
Q2 | $1.18K | Hold |
1,782
| – | – | ﹤0.01% | 6437 |
|
|
2023
Q1 | $1K | Hold |
1,782
| – | – | ﹤0.01% | 6557 |
|
|
2022
Q4 | $4K | Sell |
1,782
-42,776
| -96% | -$86.6K | ﹤0.01% | 6215 |
|
|
2022
Q3 | $86K | Sell |
44,558
-234,733
| -84% | -$852K | ﹤0.01% | 5351 |
|
|
2022
Q2 | $1.04M | Sell |
279,291
-160,513
| -36% | -$637K | ﹤0.01% | 4046 |
|
|
2022
Q1 | $2.87M | Buy |
439,804
+202,245
| +85% | +$1.51M | ﹤0.01% | 3475 |
|
|
2021
Q4 | $2.77M | Sell |
237,559
-182,803
| -43% | -$2.76M | ﹤0.01% | 3576 |
|
|
2021
Q3 | $7.83M | Buy |
420,362
+206,716
| +97% | +$3.93M | ﹤0.01% | 2626 |
|
|
2021
Q2 | $4.53M | Buy |
213,646
+187,423
| +715% | +$4.32M | ﹤0.01% | 3141 |
|
|
2021
Q1 | $532K | Buy |
26,223
+2,475
| +10% | +$67K | ﹤0.01% | 4639 |
|
|
2020
Q4 | $630K | Buy |
+23,748
| New | +$512K | ﹤0.01% | 4243 |
|
Other funds holding TSHA
RCM
ACA
VPC
RI
VCM